Methods of manufacture of pteroyl-amino acid-fluorescent dyes
Inventors
Kularatne, Sumith A. • Gagare, Pravin • Noshi, Mohammad
Assignees
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Abstract
The present invention discloses a process for preparing a compound having the formula Including Reacting a compound of the formula 1: with a compound of the formula: in the presence of a polar solvent and trifluoroacetic acid to provide a compound of the formula: or a racemic mixture thereof; and further reacting the compound of the formula: or a racemic mixture thereof; with sodium hydroxide and a compound of the formula: wherein R1 and R2 are as defined above.
Core Innovation
The disclosure describes pteroyl- or folate-targeted S0456 near-infrared fluorescent conjugates, including Pte-L-Tyr-S0456 (OTL-0038) and isotopic forms, with absorption around 650–1000 nm, preferably near 800 nm. The pterin targeting moiety directs binding to folate receptors, the tyrosine linker contributes to binding and enhanced brightness, and S0456 confers near-infrared fluorescence. Disclosed subject matter encompasses solution-phase and solid-phase peptide-synthesizer routes for producing these conjugates and specified counterion forms.
Streamlined preparation routes provide conjugates at over 98% purity via precipitation without costly chromatographic purification [procedural detail omitted for safety]. The conjugate OTL-0038 accumulates selectively in folate-receptor-positive tumors with minimal non-target uptake, yielding brighter tumor fluorescence than compared conjugates and enabling deep-tissue imaging. Documented imaging results demonstrate signal in folate-receptor-positive KB tumor xenografts, limited uptake in folate-receptor-negative A549 tumor xenografts, and kidney uptake.
Claims Coverage
The claims include four inventive features across independent claims covering general synthesis of the conjugate, specified counterion forms, isotopic forms, and solid-phase synthesis.
Synthesis of a dye-containing compound
Claim 1 covers a method for synthesizing and isolating the compound or a racemic mixture through a sequence of reactions using recited reactants, solvent, and dye. [procedural detail omitted for safety]
Synthesis with specified counterion forms
Claim 4 covers synthesis and isolation of the compound with counterions W, X, Y, and Z independently selected from H+, Na+, K+, or NH4+. [procedural detail omitted for safety]
Synthesis of an isotopic form
Claim 5 covers synthesis and isolation of an isotopic form comprising one or more isotopes selected from ²H, ³H, ¹³C, and ¹⁴C, with specified counterion alternatives. [procedural detail omitted for safety]
Solid-phase synthesis
Claim 6 covers solid-phase synthesis of the compound in a solid-phase peptide synthesizer with a resin bead and counterions W, X, Y, and Z independently selected from H+, Na+, K+, or NH4+, followed by isolation. [procedural detail omitted for safety]
The independent claims cover methods for synthesizing and isolating the targeted dye-containing conjugate in general, in specified counterion forms, as isotopic variants, and via resin-based solid-phase synthesis.
Stated Advantages
The disclosed synthesis routes produce conjugates at over 98% purity by precipitation without costly chromatographic purification.
The conjugates maintain or enhance dye fluorescence, providing improved fluorescence brightness compared to other folate–near-infrared conjugates.
The disclosure reports selective tumor targeting and deep-tissue imaging.
Documented Applications
Imaging folate receptor-positive tumors and disease tissue.
Image-guided surgery.
Deep-tissue imaging.
Near-infrared fluorescence imaging of folate-receptor-positive KB tumor xenografts, with limited uptake in folate-receptor-negative A549 tumor xenografts and kidney uptake.
Pteroyl- and folate-targeted S0456 near-infrared dyes, including Pte-L-Tyr-S0456 (OTL-0038), with absorption around 650–1000 nm, preferably near 800 nm.
Interested in licensing this patent?